UPenn sues Genen­tech over patent in­fringe­ment with four can­cer drugs

The Uni­ver­si­ty of Penn­syl­va­nia is su­ing Roche’s Genen­tech again, this time seek­ing an uniden­ti­fied amount of dam­ages for in­fring­ing on a Penn patent that’s linked to four of the Cal­i­for­nia biotech’s can­cer treat­ments and which has helped bring in bil­lions in sales over the years.

The patent in ques­tion from 2009 — known as the ‘588 patent — re­lates to ther­a­pies for treat­ing ErbB pro­tein-me­di­at­ed can­cer tu­mors, which re­late to Genen­tech’s can­cer drugs Her­ceptin, Her­ceptin Hylec­ta, Per­je­ta, and Ph­es­go.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER